 |
 |
 |
|
Insights and Experiences from the CAPELLA Trial: Perspectives of Healthcare Professionals and Study Coordinators on Lenacapavir Use Amongst Heavily Treatment-Experienced People with HIV
|
|
|
EACS 2023 Oct 18-21
Jarjieh Fang1, Olga Boiko2, Abigail N Herbst1, Megan S Dunbar3, Lauren Temme3, Keith Dunn3, Dylan Mezzio3, Martin S Rhee3, Michael Bogart3, Bridget Gaglio1, William R Lenderking1
1Evidera, Bethesda, Maryland, US; 2Evidera, London, UK; 3Gilead Sciences, Inc., Foster City, California





|
|
|
 |
 |
|
|